Clinical Trials
7 trialsNCT00263575 2024-06-18
Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT00293033 2019-11-18
Study of BEMAâ„¢ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects
BioDelivery Sciences International
Phase 3 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00458510 2013-07-11
Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain
Archimedes Development Ltd
Phase 3 Completed
NCT00641667 2013-06-07
An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain
Janssen Pharmaceutical K.K.
Phase 3 Completed
NCT00459277 2012-01-25
Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Archimedes Development Ltd
Phase 3 Completed
NCT00589823 2010-01-22
Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Archimedes Development Ltd
Phase 3 Completed